Premarin shortage possible
Executive Summary
Supply shortages of Premarin (conjugated estrogens) may occur in one or more dosage strengths, American Home Products said in its Aug. 14 10-Q filing. On Aug. 8, Wyeth-Ayerst recalled two lots totaling more than 10 mil. tablets of the 1.25 mg strength. The recall is the sixth for dissolution failure since October (1"The Pink Sheet" Dec. 11, 2000, In Brief). Wyeth and FDA are discussing problems associated with failure to meet dissolution standards
You may also be interested in...
Premarin
Class III recall of 51 lots of conjugated estrogen tablets is not related to an inspection or warning letter, Wyeth-Ayerst says. The Premarin and Premphase products involved in the Oct. 16 recall were manufactured at Wyeth's Rouses Point, N.Y. and Guayma, Puerto Rico plants. Wyeth's Pearl River, N.Y. and Marietta, Penn. injectable manufacturing plants are currently operating under an FDA consent decree. (For more information on the recall, see FDA's Dec. 6 "Enforcement Report," p. 26.)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials